JP2018530589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530589A5 JP2018530589A5 JP2018519358A JP2018519358A JP2018530589A5 JP 2018530589 A5 JP2018530589 A5 JP 2018530589A5 JP 2018519358 A JP2018519358 A JP 2018519358A JP 2018519358 A JP2018519358 A JP 2018519358A JP 2018530589 A5 JP2018530589 A5 JP 2018530589A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- cell
- cancer
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 57
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 53
- 210000004027 cell Anatomy 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- 125000004474 heteroalkylene group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 108700011259 MicroRNAs Proteins 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000000732 arylene group Chemical group 0.000 claims 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 238000007385 chemical modification Methods 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000026683 transduction Effects 0.000 claims 2
- 238000010361 transduction Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N carboxymethyl phosphonic acid Natural products OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 201000003970 colon lymphoma Diseases 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N hydroxycarbonylphosphonic acid Natural products OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- -1 rituximab Chemical compound 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022033235A JP2022081575A (ja) | 2015-10-15 | 2022-03-04 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242189P | 2015-10-15 | 2015-10-15 | |
| US62/242,189 | 2015-10-15 | ||
| PCT/US2016/057143 WO2017066639A1 (en) | 2015-10-15 | 2016-10-14 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033235A Division JP2022081575A (ja) | 2015-10-15 | 2022-03-04 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530589A JP2018530589A (ja) | 2018-10-18 |
| JP2018530589A5 true JP2018530589A5 (https=) | 2019-11-21 |
| JP7038045B2 JP7038045B2 (ja) | 2022-03-17 |
Family
ID=58517995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519358A Active JP7038045B2 (ja) | 2015-10-15 | 2016-10-14 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法 |
| JP2022033235A Pending JP2022081575A (ja) | 2015-10-15 | 2022-03-04 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033235A Pending JP2022081575A (ja) | 2015-10-15 | 2022-03-04 | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10801026B2 (https=) |
| EP (2) | EP3985116A1 (https=) |
| JP (2) | JP7038045B2 (https=) |
| CN (1) | CN108367021A (https=) |
| CA (1) | CA3001723A1 (https=) |
| WO (1) | WO2017066639A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| CN108367021A (zh) | 2015-10-15 | 2018-08-03 | 希望之城 | 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| US12404509B2 (en) | 2018-06-15 | 2025-09-02 | City Of Hope | Oligonucleotide-based proteolysis targeting chimera |
| US20220002730A1 (en) * | 2018-08-24 | 2022-01-06 | City Of Hope | Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and the uses thereof |
| WO2020172198A1 (en) * | 2019-02-18 | 2020-08-27 | Duke University | Prr-activating and microrna-inhibiting molecules and methods of using same |
| US11801266B2 (en) * | 2019-03-05 | 2023-10-31 | City Of Hope | Methods of using anti-MIR126 compounds |
| WO2021108702A1 (en) * | 2019-11-26 | 2021-06-03 | City Of Hope | Microrna as a therapeutic agent |
| US20250195666A1 (en) * | 2021-05-20 | 2025-06-19 | City Of Hope | Mir-142 compounds and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| EP1176966B1 (en) * | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
| AU2011253959B2 (en) * | 2004-05-28 | 2014-05-15 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
| US20110077215A1 (en) * | 2005-12-07 | 2011-03-31 | The University Of Utah Research Foundation | DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL) |
| EP2369011A1 (en) * | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
| CA2650026C (en) * | 2006-04-24 | 2013-01-22 | The Ohio State University Research Foundation | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
| WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| US20080214436A1 (en) * | 2007-01-26 | 2008-09-04 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| EP2134842A2 (en) * | 2007-03-07 | 2009-12-23 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial |
| US8288358B2 (en) * | 2007-03-26 | 2012-10-16 | Newcastle Innovation Ltd. | Therapeutic targets and molecules |
| CN102007408A (zh) * | 2008-02-28 | 2011-04-06 | 俄亥俄州立大学研究基金会 | 与急性髓性白血病(aml)中的细胞遗传学和预后相关的微rna特征及其用途 |
| CA2733556A1 (en) * | 2008-08-11 | 2010-02-18 | The Board Of Regents Of The University Of Texas System | A micro-rna that promotes vascular integrity and uses thereof |
| WO2010151640A2 (en) * | 2009-06-24 | 2010-12-29 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease |
| WO2011011061A2 (en) * | 2009-07-21 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy |
| WO2011116152A2 (en) * | 2010-03-16 | 2011-09-22 | Sanford -Burnham Medical Research Institute | Delivery of agents using interfering nanoparticles |
| US9006195B2 (en) * | 2010-09-13 | 2015-04-14 | California Institute Of Technology | Regulation of hematopoietic stem cell functions through microRNAs |
| EP2651445A2 (en) * | 2010-12-16 | 2013-10-23 | SPRNA GmbH | Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications |
| US9796748B2 (en) * | 2011-05-02 | 2017-10-24 | President And Fellows Of Harvard College | Spatial sequestration of dynamic nucleic acid circuits |
| AU2012308320C1 (en) | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
| CN107236735B (zh) * | 2012-06-21 | 2019-11-08 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| RS54944B1 (sr) * | 2012-07-12 | 2016-11-30 | Proqr Therapeutics Ii Bv | Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji |
| EP2890402B1 (en) * | 2012-08-31 | 2019-04-17 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| KR101467102B1 (ko) * | 2013-06-20 | 2014-12-01 | 아주대학교산학협력단 | 약물저장용 다층 구조체 및 이를 포함한 약물방출형 스텐트 |
| KR20220068276A (ko) * | 2013-09-20 | 2022-05-25 | 고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 | 면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도 |
| CN108367021A (zh) | 2015-10-15 | 2018-08-03 | 希望之城 | 包含硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法 |
-
2016
- 2016-10-14 CN CN201680073019.6A patent/CN108367021A/zh active Pending
- 2016-10-14 WO PCT/US2016/057143 patent/WO2017066639A1/en not_active Ceased
- 2016-10-14 CA CA3001723A patent/CA3001723A1/en active Pending
- 2016-10-14 JP JP2018519358A patent/JP7038045B2/ja active Active
- 2016-10-14 US US15/768,405 patent/US10801026B2/en active Active
- 2016-10-14 EP EP21203981.2A patent/EP3985116A1/en active Pending
- 2016-10-14 EP EP16856317.9A patent/EP3364984B1/en active Active
-
2020
- 2020-09-02 US US17/010,259 patent/US11591596B2/en active Active
-
2022
- 2022-03-04 JP JP2022033235A patent/JP2022081575A/ja active Pending
-
2023
- 2023-02-08 US US18/166,204 patent/US12227745B2/en active Active
-
2025
- 2025-01-10 US US19/016,464 patent/US20250207135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530589A5 (https=) | ||
| JP2022081575A5 (https=) | ||
| US12611462B2 (en) | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | |
| CN110072530B (zh) | 4′-磷酸酯类似物和包含其的寡核苷酸 | |
| JP7249080B2 (ja) | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 | |
| AU2020267142B2 (en) | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms | |
| JP2018519831A5 (https=) | ||
| IL316808A (en) | Modified double-stranded RNA materials and their uses | |
| TW202220695A (zh) | 寡核苷酸之全身遞送 | |
| CN109069528B (zh) | DBait分子在制备用于治疗三阴性乳腺癌的药物中的用途 | |
| JP2021533804A5 (https=) | ||
| JP7038045B2 (ja) | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法 | |
| KR101992925B1 (ko) | 유전자 발현 조절을 위한 올리고뉴클레오타이드 및 그 용도 | |
| JP2015513398A5 (https=) | ||
| CN116615542A (zh) | 寡核苷酸的全身递送 | |
| KR20200130856A (ko) | 암 치료에서 획득한 내성에 대한 디베이트 분자 | |
| CN121816417A (zh) | 双链寡核苷酸药剂和其用途 | |
| KR20250109208A (ko) | 올리고뉴클레오티드를 표적화하는 stat3 및 이의 용도 | |
| NZ791000A (en) | 4'-phosphate analogs and oligonucleotides comprising the same | |
| NZ767118B2 (en) | Modified double-stranded rna agents |